. 2017 Apr 18;8(24):39605–39617. doi: 10.18632/oncotarget.17174

Table 1. ATRA elicits different responses in HCT-116 and HCT-116^Sphk2 xenografted nude mice.

Cell lines	Treatment (mg/kg)	Number of mice (n)	Body weight (g)^a(initial/21 days)	Tumor weight^b(g, mean ± SD)	Tumor growth inhibition (%)
HCT-116	vehicle	6	17.9 ± 1.2/22.4 ± 1.2	1.15 ± 0.39	-
	ATRA 20	6	18.6 ± 1.1/21.2 ± 1.1	0.68 ± 0.21*	40.9
HCT-116^Sphk2	vehicle	6	18.3 ± 1.3/22.1 ± 0.9	1.04 ± 0.26	-
	ATRA 20	6	18.1 ± 0.8/20.8 ± 1.1	0.93 ± 0.24	10.6
	ATRA 30	6	18.5 ± 0.9/19.5 ± 1.2	0.86 ± 0.27	17.3

Established HCT-116 or HCT-116^Sphk2 xenografted nude mice were treated with ATRA by gavage once every three days.

^aBody weight was measured at the indicated time.

^bTumors were measured after mice were sacrificed.

*p < 0.05 vs. vehicle control.

Table 1. ATRA elicits different responses in HCT-116 and HCT-116Sphk2 xenografted nude mice.